Contrasting TESARO (TSRO) & Its Rivals
TESARO (NASDAQ: TSRO) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare TESARO to related companies based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.
This is a summary of recent ratings and price targets for TESARO and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares TESARO and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
TESARO has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, TESARO’s rivals have a beta of 7.31, suggesting that their average stock price is 631% more volatile than the S&P 500.
Institutional and Insider Ownership
50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 40.5% of TESARO shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares TESARO and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|TESARO||$44.82 million||-$387.47 million||-10.09|
|TESARO Competitors||$284.30 million||$34.29 million||137.34|
TESARO’s rivals have higher revenue and earnings than TESARO. TESARO is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
TESARO rivals beat TESARO on 8 of the 12 factors compared.
TESARO Company Profile
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.